GKOS

Glaukos Corporation

October 8, 2026 · market open

Rarity

2.89

Peak move

−14.54%

Float cap

$9.5B

Glaukos is an ophthalmic pharmaceutical and medical technology company developing therapies for glaucoma, corneal disorders and retinal diseases. It sells minimally invasive glaucoma surgery devices such as iStent to ophthalmic surgeons and hospitals, along with iDose TR, a long-duration intracameral drug delivery implant, and Photrexa/Epioxa corneal cross-linking treatments for keratoconus. Its customers are eye-care physicians, ambulatory surgery centers and payers, mainly in the United States with growing international sales.

• Key eventpeer_disclosureOct 8 · 08:07 ET

  Iantrek reported six-month topline results from a first-in-human study of bio-reinforced canaloplasty, showing mean intraocular pressure fell 37.2% from a 22.4 mmHg baseline across 52 eyes combined with cataract surgery, with 90% achieving IOP of 18 mmHg or lower.

  Webmanilatimes.net
• Key eventclinical_readoutOct 8 · 01:00 ET

  Glaukos reported positive three-year topline results from the Phase 3 GLK-202-03 extension study of Epioxa for keratoconus, with a sustained 1.9-diopter Kmax improvement, 29% of eyes gaining at least 2 lines and 20% at least 3 lines of vision, and no serious adverse events across 38 eyes.

  Webbarchart.comWebmarketscreener.comWebrttnews.comWebbusinesswire.com
• Key eventmajor_contractOct 8

  Glaukos entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a first-in-class tri-specific biologic targeting VEGF-A, VEGF-C and Ang-2 for retinal diseases, plus rights to the RevMod platform for up to four more retinal biologics, with financial terms undisclosed.

  Webbusinesswire.comWebbusinesswire.comWebmarketscreener.comWebmarketscreener.comWebtradeshownews.comWebbusinesswire.com
• insider_saleOct 8

  Glaukos disclosed three insider transactions on October 7, 2026, including executive Tomas Navratil selling 888 shares on October 5, 2026.

  Webstockpage.10jqka.com.cn
• analyst_ratingOct 7 · 19:00 ET

  Jefferies raised its price target on Glaukos to $210 from $190 while maintaining a Buy rating on the shares.

  Webkoalagains.com
• product_launchOct 7 · 16:47 ET

  Glaukos launched the "Could it be KC?" keratoconus disease awareness and educational campaign in partnership with NBA champion Stephen Curry, with expanding activities planned into 2027.

  Webtimothysykes.com
• insider_saleOct 7

  Glaukos executive Tomas Navratil sold 1,527 shares on October 5, 2026 at weighted-average prices of $163.93 to $165.60 under a Rule 10b5-1 plan adopted June 12, 2026, leaving 69,291 shares held.

  Webuk.advfn.comWebit.investing.com
• peer_disclosureOct 7

  Bausch + Lomb announced it will present new scientific data spanning cataract surgery, glaucoma and ocular surface disease at the American Academy of Ophthalmology 2026 annual meeting in New Orleans on October 9-12.

  Webeyewire.news
• earnings_releaseOct 7

  Glaukos announced it will release third-quarter 2026 financial results after the market close on Wednesday, October 28, 2026, with a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) the same day.

  Webbusinesswire.com